Clinical trial
Efficacy and Safety of Selective Intensive Induction Therapy Based on Ustekinumab Clinical Decision-making Tools in Patients With Crohn's Disease: A Multicenter, Prospective, Randomized, Controlled Study（SIIT-CD Study）
NCT05861167 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Selective Intensive Induction Therapy Based on Ustekinumab Clinical Decision-making Tools in Patients With Crohn's Disease: A Multicenter, Prospective, Randomized, Controlled Study（SIIT-CD Study）
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- June 1, 2023
- Completion date
- June 1, 2024
- Enrollment
- 140 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.